A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Number of participants with adverse events (AE) or serious adverse events (SAE)

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect. AEs include both SAEs and AEs.

Time frame: Screening, Baseline through study completion, an average of 11 weeks

Number of participants with clinically meaningful change from baseline in laboratory tests results

Time frame: Screening, Baseline, Day 2, 7 and 14

Number of participants with clinically meaningful change from baseline in vital signs

Number of participants with change from baseline in vital signs including supine blood pressure and pulse rate

Time frame: Screening, Day 1, 2, 7, 14, and 15

Number of participants with clinically meaningful change from baseline in electrocardiogram (ECG) parameters

Time frame: Screening, Day 1, 2, 7, 14 and 15

Maximal plasma concentration (Cmax)

The maximum observed plasma concentration (Cmax) will be observed directly from data.

Time frame: Day 1 and 14

Time to Maximum Plasma Concentration (Tmax)

Tmax will be observed directly from data

Time frame: Day 1 and 14

Area Under the Plasma Concentration-Time Profile From Time Zero (AUCτ) To End of Dosing Interval (AUCt)

AUCτ is summarized by dosing interval and day. Dosing interval is the interval τ between administration of doses of drug.

Time frame: Day 1 and 14

Half-life of PF-07054894

terminal elimination half-life will be calculated based on the measured data

Time frame: Day 14